Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

[News]

Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology, to be held on December 4-7 in Orlando, FL, the company announced today. Kenna Anderes, VP Cancer Biology at Cylene, will discuss research on targeting CK2, a protein kinase that is essential for the progression of multiple myeloma but that has not been previously exploited as an anticancer target.

More... (http://www.news-medical.net/news/20101207/Cylene-Pharmaceuticals-to-present-data-on-CK2-inhibitor-at-ASH-Annual-Meeting.aspx)